With GALE- stage 3 trial and revenue trends excellent
It's difficult to assess what really is going on with GALE stock and how manipulated it may be at any given time.
These low trading BIO stocks - real companies with oncology products entering the vital phase 3 that ALREADY generate revenue from other products- usually stand a better chance as they can assist with their own funding instead of diluting the Comoa got death just to try and finish the phases.
We might see w minor pullback - 1.55-1.50 range but the next break of $2 should hold with increased volume. I grabbed some under 1.50 but not enough. Will grab more. This line from a prior PR and financial has me intrigued again:
Galena-
FINANCIAL HIGHLIGHTS AND GUIDANCE
We recognize revenue from the sale of Abstral to wholesale pharmaceutical distributors, net of product-related discounts, allowances, product returns, rebates, chargebacks, and patient assistance benefits, as applicable. Because the launch of Zuplenz occurred in July, there is no revenue recorded for Zuplenz through Q2, 2015, and all revenue to date is from Abstral sales. Net revenue was $3.4 million in the second quarter of 2015, a 48% increase compared to $2.3 million reported for the same period in 2014. Net revenue was $6.1 million in the first half of 2015, a 36% increase compared to $4.5 million reported for the same period in 2014
GDTY
News 
Market Data 
Discover 
